Advertisement

Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal

Abstract

Purpose

Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal.

Methods

We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected.

Results

Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p<0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p<0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p<0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group.

Conclusions

Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.

Eur J Ophthalmol 2017; 27(6): 756 - 761

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/ejo.5000943

Authors

Sara Vaz-Pereira, Inês P. Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores, on behalf of the Portuguese Multicenter Study Group of Retinal Vascular Diseases (PORTUGAL)*

Article History

Disclosures

Financial support: Dr. Vaz-Pereira reports personal fees and nonfinancial support from Bayer and nonfinancial support from Allergan and Novartis, outside the submitted work. Dr. Flores reports personal fees and nonfinancial support from Allergan and Bayer and nonfinancial support from Novartis, outside the submitted work.
Conflict of interest: None of the authors has conflict of interest with this submission.
Meeting presentation: This work was presented as a poster at the 1st scientific meeting of the Portuguese Retina Study Group (GER), Lisbon, February 13, 2016; as a poster at the 16th ESASO Retina Academy, Estoril, Portugal, June 23-25, 2016; and as a presentation at the 16th EURETINA Congress, Copenhagen, September 8-11, 2016.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Ophthalmology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon - Portugal
  • Department of Ophthalmology, Faculty of Medicine, Universidade de Lisboa, Lisbon - Portugal
  • AIBILI Association for Innovation and Biomedical Research on Light and Image, Coimbra - Portugal
  • Department of Ophthalmology, Centro Hospitalar do Baixo Vouga, Aveiro - Portugal
  • Department of Ophthalmology, Centro Hospitalar Médio Tejo, EPE, Torres Novas - Portugal
  • Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia e Espinho, Vila Nova de Gaia - Portugal
  • Department of Ophthalmology, Centro Hospitalar de Lisboa Central, Lisbon - Portugal
  • Department of Ophthalmology, Nova Medical School, Lisbon - Portugal
  • *  Members of the Portuguese Mutlicenter Study Group of Retinal Vascular Diseases (PORTUGAL) are listed in the Appendix

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.